교정치료와 관련된 치조골 높이 변화에 대한 연구

강경화,이흥수,태기출,김상철 원광대학교 생체재료·매식연구소 1997 원광생체재료·매식 Vol.6 No.2

급성 심근경색증을 동반한 혈전성 혈소판 감소성 자반증 1예

이태희,김진혁,김완중,박지영,강흥선,조정휘,김권삼,송정상,배종화 대한순환기학회 2003 Korean Circulation Journal Vol.33 No.11

YAG LASER에 의한 공구강의 표면개질에 관한 연구

옥철호,강형식,박흥식,전태옥 韓國工作機械學會 2000 한국생산제조학회지 Vol.9 No.2

Laser induced surface hardening of Tool steel(STC5) can be achieved either with or without surface melting. In trans-formation hardening, as the surface is heated to a temperature below its melting point and is rapidly cooled, solidified microstructures are usually much finer and stronger than those of the base matals. For this reason, surface modification of tool steel by YAG laser irradiation has been studied as a fuction of processing parameters such as, power density, pulse width, defocusing distance, and molten depth. The high energy density changes and refines the microstructure of the near surface layer. In the case of beam passes, martensite formed in the melt zone exhibited very high vickers hardness values. Molten depth and width depend on defocusing distance, and energy of black color painting is more absorptive than other color painting.

연세대학교 치과병원에 내원한 어린이에서의 영구치 맹출 시기 및 순서

강태성,최병재,권호근,손홍규,최형준 大韓小兒齒科學會 2005 大韓小兒齒科學會誌 Vol.32 No.4

치아의 정확한 맹출 시기와 그 순서는 어린이의 발육 성숙도의 지표로서 소아치과 임상 및 예방 교정치료에 있어서 매우 중요하다. 이에 2001~2003년에 연세대학교 치과대학병원 소아치과에 내원한 어린이중 만 5세부터 만 14세까지의 남자 654명, 여자 542명, 총 1,196명의 자료를 수집하여 영구치의 맹출 시기 및 순서에 대한 연구 결과 다음과 같은 결론을 얻었다. 1. 상악 영구치의 맹출 시기는 중절치 남 만6.81세, 여 만6.78세, 측절치 남 만8.30세, 여 만7.98세, 견치 남 만10.28세, 여 만10.04세, 제1소구치 남 만9.74세, 여 만9.90세, 제2소구치 남 만10.87세, 여 만10.41세, 제1대구치 남 만6.25세, 여 만6.54세, 제2대구치 남 만12.21세, 여 만12.03세, 여 만12.03세였다. 2. 하악 영구치의 맹출 시기는 중절치 남 만6.00세, 여 만6.06세, 측절치 남 만6.99세, 여 만6.74세, 견치 남 만9.83세, 여 만9.17세, 제1소구치 남 만9.92세, 여 만9.75세, 제2소구치 남 만10.66세, 여 만10.39세, 제1대구치 남 만5.99세, 여 만5.75세, 제2대구치 남 만11.92세, 여 만12.17세였다. 3. 영구치의 맹출 순서는 상악에서 제1대구치, 중절치, 측절치, 제1소구치, 견치, 제2소구치, 제2대구치의 순이었고, 하악에서 제1대구치, 중절치, 측절치, 견치, 제1소구치, 제2소구치, 제2대구치의 순이었다. Accurate timing and sequence of eruption of permanent teeth are indicies of growth and essential for pediatric dentistry and pediatric clinical orthodontics. From the children brought to the Yonsei Dental Hospital during 2001 to 2003, 654 boys and 542 girls, ranging in age from five to fourteen years, were selected and analysed. The following was concluded. 1. Eruption time of maxillary teeth is 6.81 years in boys, 6.78 years in girls for central incisor, 8.30 years in boys, 7.98 years in girls for lateral incisor, 10.28 years in boys, 10.04years in girls for canine, 9.74 years in boys, 9.90 years in girls for first premolar, 10.87 years in boys, 10.41 years in girls for second premolar, 6.25 years in boys, 6.54 years in girls for first permanent molar, 12.21 years in boys, 12.03 years in girls for second permanent molar. 2. Eruption time of mandibular teeth is 6.00 years in boys, 6.06 years in girls for central incisor, 6.99 years in boys, 6.74 years in girls for lateral incisor, 9.83 years in boys, 9.17 years in girls for canine, 9.92 years in boys, 9.75 years in girls for first premolar, 10.66 years in boys, 10.39 years in girls for second premolar, 5.99 years in boys, 5.75 years in girls for first permanent molar, 11.92 years in boys, 12.17 years in girls for second permanent molar. 3. The following eruption sequence was observed: the first permanent molar erupted first, followed by the central incisor, the lateral incisor, the first premolar, the canine, the second premolar and the second permanent molar in the maxilla. The first permanent molar erupted first, followed by the central incisor, the lateral incisor, the canine, the first premolar, the second premolar and the second permanent molar in the mandible.

융모성 질환의 임상적 연구

남상륜,손영선,이영일,노흥태,강길전 충남대학교 의과대학 지역사회의학연구소 1989 충남의대잡지 Vol.16 No.2

Seventy nine cases of trophoblastic disease were analyzed at the Department of Obstetrics and Gynecology, Chungnam National University from January, 1985 to October, 1989. The results are as follows: 1. Incidence of trophoblastic disease was one per 31.8 deliveries(3.15%), and it was pathologically consisted with partial mole(27.8%), complete mole(45.6%), invasive mole (17.7%), choriocarcinoma(8.9%). 2. Age group of 26 to 30 was found most frequent(40.5%) and primipara was the most frequent group(43.0%). There was no increase for the persistent disease according to age and para. 3. Clinical manifestations were vaginal bleeding(91.1%), the most common, nausea and vomiting(20.3%), abdominal pain(10.1%) and etc. 4. Molar pregnancies with excessive uterine enlargement were found in 35.6% and were at increased risk for the persistent disease. 5. Antecedant pregnancies prior to trophoblastic disease were abortion(43.0%), term pregnancy(16.5%) and molar pregnancy(16.5%). 6.β-hCG concentration before November, 1986 was significantly lower than after ten. And the first postevacuation β-hCG level was increased in cases of the persistent disease. 7. The treatment regimens in molar pregnancies were suction curettage with prophylactic Act-D(41.4%) and without Act-D(43.1%), hysterectomy with Act-D(13.8%), and hysterotomy(1.7%). There was no difference in complication persistent disease between with and without prophylactic chemotherapy. 8. Non-metastatic and metastatic low risk patients were treated with hysterectomy with or without MTX-CF(66.7%), curettage with MTX-CF, Act-D or MAC(33.3%) to attain remission without failure. All metastatic high risk patients were treated with hysterectomy with 1-6 courses of MAC triple chemotherapy except 1 case of death from respiratory failure and 1 lost case. 9. Side effects after chemotherapy include gastrointestinal symptoms(91.1%), fever(57.8%), leukopenia(49.0%), hepatotoxicity(46.9%), stomatitis(40%), alopecia(28.9%), thrombocytopenia(15.3%) and etc, in order of frequency.

혈액투석중인 만성신부전 환자에서 골대사 지표로써의 Osteocalcin치

송치운,이진홍,안미애,윤환중,윤상임,성기양,이강현,송민호,이강욱,신영태,김영건,노흥규 충남대학교 의과대학 지역사회의학연구소 1993 충남의대잡지 Vol.20 No.2

Background : Serum osteocalcin is synthesized by osteoblast and has been shown to be sensitive indicator of bone turnover inpatients with various metabolic bone disease. In renal osteodystrophy, serum osteocalcin is elevated due to decreased renal clearance and elevated level of PTH. This study was done to evaluate the usefulness of serum osteocalcin as a marker of bone metabolism and the correlation with other biochemical markers of bone metabolism. Methods : We measured serum osteocalcin, calcium, phosphorus, ALP(alkaline phosphatase) and PTH(parathyroid hormone) in 37 patients with end stage renal disease on hemodialysis. Osteocalcin was determined by radioimmunoassay and PTH was determined by radioimmunometric assay. Results : 1) The mean level of serum osteocalcin in ESRD patients was 233.8± 218.2ng/ml which was significantly higher than that of controls(p<0.0001). 2) The mean level of serum PTH in ESRD patients was 40.5± 43.8pg/ml was significantly higher than that of controls(p<0.005). 3) There was a significant positive correlation between the level of serum PTH, ALP and the level of serum osteocalcin in ESRD patients. 4) By using multiple regression, PTH is most reliable factor that affect to elevated level of serum osteocalcin ( beta coefficient = 0.687, Sig T<0.05). Conclusion : Serum osteocalcin as a marker of bone metabolism in ESRD patients is more useful than other biochemical marker such as serum calcium, phosphorus, ALP and PTH is a most reliable factor that affect to elevated level of serum osteocalin.

간장 ( 肝腸 ) 및 담도 ( 膽道 ) : I - 131 - Lipiodol의 간동맥주입과 간동맥 색전술에 의한 원발성 간암 치료 효과

강진경(Jin Kyung Kang),최흥재(Heung Jai Choi),박인서(In Suh Park),이상인(Sang In Lee),한광협(Kwang Hyub Han),전재윤(Chae Yoon Chon),이종태(Jong Tae lee),유형식(Hyung Sik Yoo),한승희(Seung Hee Han),노재경(Jae Kyung Roh) 대한소화기학회 1990 대한소화기학회지 Vol.22 No.3

N/A Lipiodol (iodized oil) is known to be selectively retained for an extended duration in hepatocellular carcinoma (HCC), so a number of therapeutic trials using Lipiodol in patients with HCC have been performed. Hepatic arterial infusion of radiolabelled iodized oil (I-131-Lipiodol) has potential as a radiotherapeutic agent in patiens with HCC. This study was undertaken to assess the therapeutic efficacy of hepatic arterial infusion of I-131-Lipiodol alone or I-131-Lipiodol combined with transcath- eter arterial embolization (TAE) in comparison with conventional TAE in patients with HCC. From March 1985 to December 1988, 136 patients with HCC were given eithep an hepatic arterial infusion of I-131-Lipiodol alone (Group 1, n=83), TAE with Ivalon or GelfoaO (Group 2, n=23) or infusion of I-131-Lipiodol combined with TAE (Group 3, n=30). There was no significant difference in sex, age, tumor size and type, biochemical tests, and Child classification among the 3 groups. We analyzed the response rate and survival rate according to the therapeutic modality and tumor size. 1) The response rates were 32.5, 43.5, and 73.3% in groups 1,2, and 3 respectively and the response rate in group 3 was significantly higher than group 1 (p<0.05). (response was defined as a decrease more than 2.5% in tumor size 3 months after treatment). 2) There was no significant difference in response rate among the 3 groups in tumors smaller than 5 cm, but the response rate of group 3 (71.4%) was significantly higher than group 1 (27.9%) in tumors larger than 5 cm (p<0.05). 3) The survival rate among tumors smaller than 5 cm was significantly highter than among tumors larger than 5 cm (p<0.05).

Discover of a male of Okinawa gypsy moth, Lymantria albescens trapped in sex-pheromone trap for AGM, Lymantria dispar

Heung-Sik Lee,Tae Hwa Kang,Gwangsu Lee 한국응용곤충학회 2014 한국응용곤충학회 학술대회논문집 Vol.2014 No.04

A male specimen of Lymantria albescens (called as Okinawa gypsy moth) was captured in Busan, by sex-pheromone trap for Asian Gypsy Moth (AGM) (7R,8S)-cis-7,8-epoxy-2- methyloctadecane [(+)-disparlure]. Up to now, this species is distributed only in Ryukyu Islands of Japan including Ishigaki and Okinawa. The male of Okinawa gypsy moth might be attracted to AGM pheromone trap. If L. albescens is occurred in Korea, more many male individuals must be captured in pheromone trap. Therefore, we considered that the individual might be imported from Japan by inanimate pathway. Although it is high probability that L. albescens might be imported from Okinawa, it is important to a survey on an invasive pathway of the species in a view point of quarantine inspection. Through this presentation, we provided a detection method on Lymantria species using DNA barcoding. On the basis of this study, we will conduct on an invasive pathway and inhabitation possibility.

Modification of dendritic cells with interferon-γ-inducible protein-10 gene to enhance vaccine potency

Kang, Tae Heung,Bae, Hyun Cheol,Kim, Seok-Ho,Seo, Su Hong,Son, Sang Wook,Choi, Eun Young,Seong, Seung-Yong,Kim, Tae Woo John Wiley Sons, Ltd. 2009 The journal of gene medicine Vol.11 No.10

<B>Background</B><P>Dendritic cell (DC)-based vaccines have become a promising modality in cancer immunotherapy. However, their ability to initiate tumor antigen-specific T cell immunity is limited in various negative-feedback mechanisms. The rapid down-regulation of chemokines, such as the interferon inducible protein of 10 kDa (IP-10), which chemoattracts activated antigen-specific CD8<SUP>+</SUP> T cells, would represent negative-feedback regulation. Therefore, we attempted to improve DC vaccine potency by introducing the IP-10 gene retrovirally aiming to replenish the chemoattractive activity of DCs.</P><B>Methods</B><P>We introduced IP-10 gene into DC2.4 cells, referred to as DC-IP10, using a retroviral system. Nonsecretable mIP-10-expressing DCs (DC-mIP10) were also prepared to evaluate the effects of secretion in IP-10-mediated modulation of DC biology. Additionally, in vitro and in vivo activation of antigen-specific T lymphocytes and in vivo anti-tumor effects induced by DC-IP10 or DC-mIP10 were determined.</P><B>Results</B><P>The modification of DC2.4 cells with the IP-10 gene resulted in the secretion of functionally chemoattractive IP-10 and, unexpectedly, a significant up-regulation of surface expression in co-stimulatory molecules, such as CD40 and CD80, compared to that of DCs with vector control (DC-no insert). DC-mIP10 also displayed the partially matured phenotypes but failed to recruit antigen-specific T cells in an in vitro cell culture system. Consistently, DC-IP10 generated more tumor antigen-specific CD8<SUP>+</SUP> T cells and stronger anti-tumor effects in vaccinated mice than did control DCs and DC-mIP10.</P><B>Conclusions</B><P>The results obtained provide the groundwork for a future clinical translation of the chemokine-based genetic modification of DCs to increase their vaccine potency. Copyright © 2009 John Wiley & Sons, Ltd.</P>

Enhancement of DNA vaccine potency by antigen linkage to IFN‐γ‐inducible protein‐10

Kang, Tae Heung,Kim, Keon Woo,Bae, Hyun Cheol,Seong, Seung‐,Yong,Kim, Tae Woo Wiley Subscription Services, Inc., A Wiley Company 2011 International journal of cancer: Journal internati Vol.128 No.3

<P><B>Abstract</B></P><P>DNA vaccines have emerged as an attractive approach to generate antigen‐specific T‐cell immune response. Nevertheless, the potency of DNA vaccines still needs to be improved for cancer immunotherapy. In this study, we explored whether functional linkage of a Th1‐polarizing chemokine, IP‐10, to a model tumor antigen, human papillomavirus type 16 (HPV‐16) E7, enhanced DNA vaccine potency. IP‐10 linkage changed the location of E7 from the nucleus to the endoplasmic reticulum and led to the secretion of functionally chemoattractive chimeric IP‐10/E7 protein. In addition, this linkage drastically enhanced the endogenous processing of E7 antigen through MHC class I. More importantly, we found that C57BL/6 mice intradermally vaccinated with IP‐10/E7 DNA exhibited a dramatic increase in the number of E7‐specific CD4<SUP>+</SUP> Th1 T‐cells and CD8<SUP>+</SUP> T‐cells and, consequently, were strongly resistant over the long term to E7‐expressing tumors compared to mice vaccinated with wild‐type E7 DNA. Thus, because of the increase in tumor antigen‐specific T‐cell immune responses obtained through both enhanced antigen presentation and chemoattraction, vaccination with DNA encoding IP‐10 linked to a tumor antigen holds great promise for treating tumors.</P>